
Home » Regeneron Begins Phase 3 Trial of Antibody Cocktail for COVID-19
Regeneron Begins Phase 3 Trial of Antibody Cocktail for COVID-19

Regeneron Pharmaceuticals has begun a phase 3 clinical trial in the U.S. of its antibody cocktail REGN-COV2 for the prevention of COVID-19 infections.
The trial is being conducted with the National Institutes for Allergy and Infectious Diseases and plans to enroll 2,000 patients across 100 sites.
The company has also launched two phase 2/3 trials evaluating the cocktail’s ability to treat patients already infected with COVID-19.
Upcoming Events
-
08Feb
-
09Feb
-
15Feb
-
16Feb
-
22Feb
-
07Mar